OncRef

Clinical Trial: NCT05376878

An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis

Status:

RECRUITING

Phase:

Phase 4

Lead Sponsor:City of Hope Medical Center
Information Provided By:City of Hope Medical Center
Last Update Posted:2026-07-01

Study Overview

Brief Summary

This clinical trial examines an investigational scan (64Cu-DOTA-trastuzumab positron emission tomography [PET]/magnetic resonance imaging [MRI]) in imaging patients with HER2+ breast cancer that has spread to the brain (brain metastasis). Diagnostic procedures, such as 64Cu-DOTA-trastuzumab PET/MRI, may help find HER2+ breast cancer that has spread to the brain and determine whether cancer in the brain takes up trastuzumab, which may predict for response to trastuzumab deruxtecan (the standard of care chemotherapy).

Official Title

Pilot Study to Evaluate 64Cu-DOTA-Trastuzumab Imaging in Patients With HER2+ Breast Cancer With Brain Metastatsis Treated With Fam-Trastuzumab Deruxtecan

Conditions

Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain

Intervention / Treatment

  • Other: Copper Cu 64-DOTA-Trastuzumab
  • Procedure: Magnetic Resonance Imaging
  • Device: Positron Emission Tomography
  • Biological: Trastuzumab
  • Biological: Trastuzumab Deruxtecan

Other Study ID Numbers

  • 21050
  • NCI-2022-03220
  • 21050
  • P30CA033572

Start Date (Actual)

2022-12-21

Primary Completion Date (Estimated)

2027-04-27

Study Completion Date (Estimated)

2027-04-27

Enrollment (Estimated)

10

Study Type

Interventional

Phase

Phase 4